Taken together, these results indicate that tPDT by fVII to TF could not only distinguish tumour cells from normal cells but could also distinguish tumour angiogenic VECs from normal quiescent VECs.", "sentences": [], "annotations": [], "relations": []}, {"offset": 29320, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Improved effect of fVII-targeted PDT as compared to ntPDT", "sentences": [], "annotations": [], "relations": []}, {"offset": 29378, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "The PDT results with breast cancer cell lines showed that the effect of tPDT was stronger than those of ntPDT on killing both human and mouse breast cancer MDA-MB-231 and EMT6 cells with a VP concentration-dependent response and that fVII targeting decreased by about three to four fold the EC50 concentration of VP (Figure 4A-B), indicating that fVII targeting improved the effect. Moreover, when the VP concentration was 2 muM, the EC50 of the laser energy in tPDT was about half of that in ntPDT (Figure 4C), further indicating that fVII targeting could also reduce laser exposure, which could decrease the risk of side effects of ntPDT.", "sentences": [], "annotations": [], "relations": []}, {"offset": 30019, "infons": {"file": "1471-2407-10-235-4.jpg", "id": "F4", "section_type": "FIG", "type": "fig_caption"}, "text": "fVII targeting enhances the therapeutic effect of VP PDT for human and mouse breast cancer cells. A and B. fVII targeting decreased the EC50 (crossing with dotted lines) concentration of VP in fVII-tPDT by three to four fold for human (MDA-MB-231) (A) and mouse (EMT6) (B) breast cancer lines, compared to ntPDT (689 nm laser for 60 J/cm2). C. fVII targeting also decreased the EC50 (crossing with dotted line) of the laser energy for VP PDT (2 muM VP). D. The effect of fVII-targeted VP PDT (2 muM VP, 689 nm laser for 60 J/cm2) could be inhibited by unconjugated mfVII. Results in A-C are representative of two experiments.", "sentences": [], "annotations": [], "relations": []}, {"offset": 30645, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "As shown in Figure 4D, the effect of fVII-tPDT, presented as percent of surviving cells, was partially inhibited at a ratio of 1:1 (unconjugated mfVII: VP-conjugated mfVII) (59.4 +- 0.4%) and almost completely inhibited at ratios of 10:1 and 50:1 (90.6 +- 5.9% and 94.8 +- 4.7%, respectively), as compared to no addition of mfVII (cell survival percent was 37.4 +- 14.8% at the ratio of 0:1) (P > 0.05, < 0.05 and < 0.01 for 0:1 vs. 1:1, 10:1 and 50:1, respectively, by one-way ANOVA), indicating that the effect was mediated by mfVII binding to TF.", "sentences": [], "annotations": [], "relations": []}, {"offset": 31195, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Killing mechanisms induced by VP PDT", "sentences": [], "annotations": [], "relations": []}, {"offset": 31232, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "The results in Figure 5 show that both apoptosis and cytotoxicity were induced in the MDA-MB-231 cancer cells treated by tPDT and ntPDT, but tPDT induced significantly stronger apoptosis (Figure 5A) and cytotoxicity (Figure 5B) than ntPDT (P < 0.0001 by one-way ANOVA with Tukey's Multiple Comparison Test), which was consistent with the results of therapeutic effect as determined by clonogenic assay (Figure 5C) (P < 0.0001). The Caspase 3/7 activity was the highest at 12 hrs compared to those at 8 and 16 hrs after PDT, and the LDH activity in the cytotoxicity assays was higher at 1 hr than that at 4 hrs after PDT.", "sentences": [], "annotations": [], "relations": []}, {"offset": 31853, "infons": {"file": "1471-2407-10-235-5.jpg", "id": "F5", "section_type": "FIG", "type": "fig_caption"}, "text": "fVII-tPDT induces stronger levels of apoptosis and cytotoxicity (necrosis) than ntPDT in human breast cancer MDA-MB-231 cells. Both fVII-tPDT and ntPDT were carried out at 2 muM VP and 60 J/cm2. A. Apoptosis assay for Caspase 3/7 activity in the PDT-treated cancer cells. B. Cytotoxicity assay for LDH release from PDT-treated cancer cells into the culture medium. C. PDT therapeutic effect assayed by crystal violet staining.", "sentences": [], "annotations": [], "relations": []}, {"offset": 32280, "infons": {"section_type": "RESULTS", "type": "title_2"}, "text": "Effect of tPDT on cancer in vivo in mice bearing mouse breast cancer", "sentences": [], "annotations": [], "relations": []}, {"offset": 32349, "infons": {"section_type": "RESULTS", "type": "paragraph"}, "text": "As shown in Figure 6A, fVII-tPDT at 2 muM of VP was effective in inhibiting the tumour growth of murine breast cancer in mice (P < 0.01 vs. control by one-way ANOVA with Tukey's Multiple Comparison Test) (3-4 mice per group in Figure 6A). In contrast, ntPDT did not have any effect (P = 0.